## Susana Otero-Romero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3090351/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	1.4	458
2	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	3.7	403
3	<scp>ECTRIMS</scp> / <scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237.	1.7	147
4	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis Journal, 2016, 22, 1386-1396.	1.4	118
5	COVIDâ€19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. European Journal of Neurology, 2021, 28, 3384-3395.	1.7	111
6	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	1.4	77
7	Retinal microvascular abnormalities in patients after COVID-19 depending on disease severity. British Journal of Ophthalmology, 2022, 106, 559-563.	2.1	64
8	Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	1.4	60
9	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.5	49
10	Multiple sclerosis registries in Europe – An updated mapping survey. Multiple Sclerosis and Related Disorders, 2019, 27, 171-178.	0.9	47
11	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.5	42
12	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	1.4	41
13	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35
14	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.5	32
15	Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain. Multiple Sclerosis Journal, 2013, 19, 245-248.	1.4	29
16	Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Current Opinion in Neurology, 2021, 34, 322-328.	1.8	23
17	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	1.7	20
18	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1143.	3.1	17

#	Article	IF	CITATIONS
19	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	1.7	16
20	Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español. NeurologÃa, 2021, 36, 50-60.	0.3	15
21	Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Review of Clinical Immunology, 2021, 17, 285-300.	1.3	12
22	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	1.4	11
23	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	1.8	10
24	Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. Journal of the Neurological Sciences, 2015, 359, 146-150.	0.3	8
25	Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection. Vaccines, 2021, 9, 1463.	2.1	8
26	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	1.4	7
27	Persistent reduction of retinal microvascular vessel density in patients with moderate and severe COVID-19 disease. BMJ Open Ophthalmology, 2022, 7, e000867.	0.8	7
28	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Multiple Sclerosis Journal, 2018, 24, 721-727.	1.4	6
29	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	1.8	5
30	Multiple sclerosis is associated with higher comorbidity and health care resource use: A populationâ€based, case–control study in a western Mediterranean region. European Journal of Neurology, 2021, 28, 4124-4134.	1.7	4
31	Impacto de la vacunación de las embarazadas frente a la tosferina en las hospitalizaciones de menores de un año en un hospital de tercer nivel de Cataluña. Enfermedades Infecciosas Y MicrobiologÃa Clápica, 2022, 40, 473,478	0.3	2